MCM
SAGE

Mason Capital Management’s Sage Therapeutics SAGE Stock Holding History

Mason Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,300
Closed -$415K – 42
2021
Q2 		$415K Buy
+7,300
New +$516K 0.03% 30

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Mason Capital Management's SAGE Position: Q3 2021 in Review

Mason Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 7,300 shares — an estimated $415K sold.

Mason Capital Management first reported a position in SAGE in Q2 2021 and held it in 1 quarter. The position peaked at $415K in Q2 2021. 225 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

  • Mason Capital Management reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Mason Capital Management sold 7,300 Sage Therapeutics shares in Q3 2021, an estimated $415K.
  • Mason Capital Management first reported a position in Sage Therapeutics in Q2 2021 and held it in 1 quarter.
  • Mason Capital Management's Sage Therapeutics position peaked at $415K in Q2 2021.
  • 225 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on Mason Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.